The Journal of Infectious Diseases (J INFECT DIS)

Publications in this journal

• Article: An ATP2B4 polymorphism protects against malaria in pregnancy.

  Beddu-Addo G, Meese S, Mockenhaupt F
  [show abstract] [hide abstract]
  ABSTRACT: Polymorphisms of ATP2B4 encoding an ubiquitous Ca2+-pump protect against severe childhood malaria. We assessed the influence of a main polymorphism (rs10900585) on malaria among 834 delivering Ghanaian women. In homozygous primiparae, the odds of placental Plasmodium falciparum infection were reduced by 64%. No influence of the polymorphism on parasite density, low birth weight or preterm delivery was discernible. However, malarial anemia was greatly reduced in primiparous variant allele carriers paralleling the reduced impact of malaria on hemoglobin levels in this group. A common ATP2B4 polymorphism protects from malaria in pregnancy and related anemia suggesting mechanisms non-exclusive for severe childhood malaria.
  The Journal of Infectious Diseases 02/2013;
• Article: Pharmacodynamic and Antiretroviral Activitiesof Combination Nanoformulated Antiretroviralsin HIV-1–Infected Human Peripheral BloodLymphocyte–Reconstituted Mice

  Roy U, McMillan J, Alnouti Y, Gautum N, Smith N, Balkundi S, Dash P, Gorantla S, Martinez-Skinner A, Meza J, Kanmogne G, Swindells S, Cohen SM, Mosley RL, Poluektova L, Gendelman HE
  The Journal of Infectious Diseases 07/2012;
• Article: Gene Polymorphism in Toll-like Receptor 4: Effect on Antibody Production and Persistence After Acellular Pertussis Vaccination During Adolescence.

  Gröndahl-Yli-Hannuksela K, Vuononvirta J, Barkoff AM, Viander M, Van Der Meeren O, Mertsola J, He Q
  The Journal of Infectious Diseases 03/2012;
• Article: Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

  Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F
  The Journal of Infectious Diseases 02/2012;
• Article: Influenza Vaccination for ImmunocompromisedPatients: Systematic Review and Meta-analysisby Etiology

  Charles R. Beck, Bruce C. McKenzie, Ahmed B. Hashim, Rebecca C. Harris, University of Nottingham Influenza, Arina Zanuzdana in UNIIC Study Group, and Jonathan S. Nguyen-Van-Tam
  [show abstract] [hide abstract]
  ABSTRACT: Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and metaanalyses to assess the evidence for influenza vaccination in this group, and we report our results by etiology. Meta-analyses showed significantly lower odds of influenza-like illness after vaccination in patients with human immunodeficiency virus (HIV) infection, patients with cancer, and transplant recipients and of laboratory-confirmed influenza in HIV-positive patients, compared with patients receiving placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive patients, patients with cancer, and transplant recipients, compared with immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between etiological groups. Limited evidence of a transient increase in viremia and a decrease in the percentage of CD4+ cells in HIV-positive patients was found although not accompanied by worsening of clinical symptoms. Clinical judgment remains important when discussing the benefits and safety profile with immunocompromised patients.
  The Journal of Infectious Diseases 01/2012; 206:1250-9.
• Article: The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study

  Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
  [show abstract] [hide abstract]
  ABSTRACT: Abstract We assessed whether fasting modifies the prognostic value of these measurements for the risk of myocardial infarction (MI). Analyses used mixed effect models and Poisson regression. After confounders were controlled for, fasting triglyceride levels were, on average, 0.122 mmol/L lower than nonfasting levels. Each 2-fold increase in the latest triglyceride level was associated with a 38% increase in MI risk (relative rate, 1.38; 95% confidence interval, 1.26-1.51); fasting status did not modify this association. Our results suggest that it may not be necessary to restrict analyses to fasting measurements when considering MI risk.
  The Journal of Infectious Diseases 08/2011; 204(4):521.
• Article: Programmed Death 1 and Cytokine Inducible SH2-containing Protein Dependent Expansion of Regulatory T Cells

  Periyasamy S, Dhiman R, Barnes PF, Paidipally P, Tvinnereim A, Bandaru A, Valluri V and Vankayalapati R
  The Journal of Infectious Diseases 01/2011; 203(9):1256=1263.
• Article: Both CD31+ and CD31� Naive CD4+ T CellsAre Persistent HIV Type 1–Infected Reservoirsin Individuals Receiving Antiretroviral Therapy

  Fiona Wightman, Ajantha Solomon, Gabriela Khoury, Justin A Green, Lachlan Gray, Paul R Gorry, Yung Shwen Ho, Nitin K. Saksena, Jennifer Hoy, Suzanne M. Crowe, Paul U. Cameron, Sharon R. Lewin
  [show abstract] [hide abstract]
  ABSTRACT: Background. Naive T cell recovery is critical for successful immune reconstitution after antiretroviral therapy (ART), but the relative contribution of CD31+ and CD31� naive T cells to immune reconstitution and viral persistence is unknown. Methods. In a cross-sectional (np94) and longitudinal (np10) study of human immunodeficiency virus (HIV)–infected patients before and after ART, we examined the ratio of CD31+ to CD31� naive CD4+ T cells. In the longitudinal cohort we then quantified the concentration of HIV-1 DNA in each cell subset and performed single-genome amplification of virus from memory and naive T cells. Results. Patients receiving ART had a higher proportion of CD31+ CD4+ T cells than HIV-1–infected individuals naive to ART and uninfected control subjects (P!.001 and .007, respectively). After 24 months of ART, the proportion of CD31+ naive CD4+ T cells did not change, the concentration of HIV-1 DNA in memory CD4+ T cells significantly decreased over time (P!.001), and there was no change in the concentration of HIV-1 DNA in CD31+ or CD31� naive CD4+ T cells (Pp.751 and .251, respectively). Single-genome amplification showed no evidence of virus compartmentalization in memory and naive T cell subsets before or after ART. Conclusions. After ART, both CD31+ and CD31� naive CD4+ T cells expand, and both subsets represent a stable, persistent reservoir of HIV-1.
  The Journal of Infectious Diseases 12/2010;
• Article: Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture.

  Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, Brown KE, Burge CB, Schmidt WN, Wang Y, McCaffrey AP
  The Journal of Infectious Diseases 06/2010;
• Article: Role played by psrP-secY2A2 (accessory region 34) in the invasive disease potential of Streptococcus pneumoniae.

  Carlos J Orihuela
  The Journal of Infectious Diseases 11/2009; 200(7):1180-1; author reply 1181-2.
• Article: Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.

  Gabriela Paz-Bailey, Maya Sternberg, Adrian J Puren, Lauri E Markowitz, Ronald Ballard, Sinead Delany, Sarah Hawkes, Okey Nwanyanwu, Caroline Ryan, David A Lewis
  [show abstract] [hide abstract]
  ABSTRACT: It is uncertain whether episodic acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation. A double-blind, randomized, placebo-controlled trial of 5-day acyclovir (400 mg 3 times daily) was conducted among men with genital ulcers in South Africa. Participants received syndromic management; were tested for ulcer etiology, human immunodeficiency virus (HIV), syphilis, and herpes simplex virus type 2 (HSV-2); and were seen over the course of a month to evaluate ulcer healing and HIV-1 RNA shedding. Outcomes were ulcer duration and HIV-1 RNA shedding, assessed on day 7 among HIV-1-seropositive participants with a herpetic ulcer. A total of 309 men received acyclovir, and 306 received placebo; 63% were HIV-1 positive. There were 295 HIV-1-positive participants with a herpetic ulcer. Acyclovir improved ulcer healing--61% of those receiving acyclovir healed by day 7, compared with 42% of those receiving placebo (adjusted relative risk, 1.4 [95% confidence interval, 1.1-1.8]; P= .003). Acyclovir also improved healing by a median of 3 days (P= .002) and reduced HIV-1 ulcer shedding on day 7 (24% for acyclovir vs 37% for placebo; P= .05). Addition of acyclovir to syndromic management will improve healing of genital ulcers and may potentially reduce HIV transmission in combination with other interventions.
  The Journal of Infectious Diseases 11/2009; 200(7):1039-49.
• Source

  Available from: oxfordjournals.org

  Article: Reply to orihuela.

  Birgitta Henriques-Normark
  The Journal of Infectious Diseases 11/2009; 200(7):1181-2.